David Matuskey, MD
Associate Professor of Radiology and Biomedical ImagingCards
Appointments
Additional Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging
Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
Appointments
Additional Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging
Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
Appointments
Additional Titles
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging
Medical Director, Yale Positron Emission Tomography (PET) Center
Contact Info
About
Copy Link
Titles
Associate Professor of Radiology and Biomedical Imaging
Director, NeuroPET Imaging Program, Radiology and Biomedical Imaging; Medical Director, Yale Positron Emission Tomography (PET) Center
Biography
I am a board certified psychiatrist and neuropsychiatrist with research work that has been translational in nature and focused on elucidating the underlying pathology of brain conditions such as Autism Spectrum Disorder, substance abuse and neuropsychiatric disorders (e.g., Parkinson's disease) with an aim to find effective clinical treatments guided by molecular neuroimaging. Studies have included using in vivo PET imaging to investigate the role of neuroreceptors such as dopamine D3, serotonin 1B and 6, MGlur5 and kappa opioid systems, neuroinflammation, and most recently, synaptic density (SV2A) in clinical and nonclinical populations. Ongoing interests include imaging neuropsychiatric and addictive disorders and the demographic, social and environmental factors influencing our brain.
Appointments
Radiology & Biomedical Imaging
Associate Professor on TermPrimaryNeurology
Assistant ProfessorSecondaryPsychiatry
Associate Professor on TermSecondary
Other Departments & Organizations
- Bioimaging Sciences
- Center for Brain & Mind Health
- Connecticut Mental Health Center
- Mental Health PET Radioligand Development (MHPRD) Program
- Movement Disorders Division
- MR Core
- Neurology
- NeuroPET Imaging Program
- PET Core
- Psychiatric Symptoms in Neurology Research Program
- Psychiatry
- Radiology & Biomedical Imaging
- Yale Biomedical Imaging Institute
- Yale Cocaine Research Clinic
Education & Training
- Clinical Neuroscience Research Fellow
- Yale University (2010)
- Senior Resident
- Yale University (2009)
- Resident
- University of Connecticut (2008)
- MD
- St Matthew's University School of Medicine (2005)
- BA
- University of South Florida, Psychology (1998)
- BS
- University of South Florida, Biology (1998)
Research
Copy Link
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0001-7508-6572
Research Projects
In vivo synaptic and dopamine transporter imaging in Parkinson's disease
Neurology / , parent organization of Movement Disorders Division
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Richard Carson, PhD
Nabeel Nabulsi, PhD
Jean-Dominique Gallezot, PhD
Yiyun Huang, PhD
Mika Naganawa, PhD
Kelly Cosgrove, PhD
Neuroimaging
Parkinson Disease
Mental Disorders
Frontotemporal Dementia
Social Class
Molecular Imaging
Publications
2026
Widespread synaptic density loss in schizophrenia follows molecular and network architecture
Chopra S, Worhunsky P, Naganawa M, Zhang X, Segal A, Labache L, Orchard E, Cropley V, Wood S, Angarita G, Cosgrove K, Matuskey D, Nabulsi N, Huang Y, Carson R, Esterlis I, Skosnik P, D’Souza D, Holmes A, Radhakrishnan R. Widespread synaptic density loss in schizophrenia follows molecular and network architecture. Molecular Psychiatry 2026, 1-12. PMID: 42350786, DOI: 10.1038/s41380-026-03717-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricNeuroimaging evidence for a dopamine-independent association between motor cortex microstructure and Parkinson’s disease severity
Honhar P, Tinaz S, Ebrahimian Sadabad F, Dias M, Yang Y, Henry S, Hillmer A, Zakiniaeiz Y, Radhakrishnan R, Comley R, Zhang X, Hooker B, Zhang Y, Finnema S, Carson R, Scheinost D, Matuskey D. Neuroimaging evidence for a dopamine-independent association between motor cortex microstructure and Parkinson’s disease severity. Npj Parkinson's Disease 2026 PMID: 42248873, DOI: 10.1038/s41531-026-01411-x.Peer-Reviewed Original ResearchImpulsivity, reward sensitivity, and dopamine 2/3 receptors availability in people with cocaine use disorder: A [11C]PHNO PET study
Mayeli M, Worhunsky P, Carson R, Potenza M, Angarita G, Matuskey D. Impulsivity, reward sensitivity, and dopamine 2/3 receptors availability in people with cocaine use disorder: A [11C]PHNO PET study. Psychiatry Research 2026, 364: 117239. PMID: 42229023, DOI: 10.1016/j.psychres.2026.117239.Peer-Reviewed Original ResearchAltmetricLower synaptic density in mood circuitry underlies depression in Parkinson’s disease
Cayir S, Naganawa M, Volpi T, Sadabad F, Dias M, Yang Y, Elliott S, Ansari M, Elshahat A, Pittman B, Esterlis I, Nabulsi N, Huang Y, Sanacora G, Comley R, Finnema S, Carson R, Tinaz S, Matuskey D, Holmes S. Lower synaptic density in mood circuitry underlies depression in Parkinson’s disease. Brain Communications 2026, 8: fcag136. PMID: 42109687, PMCID: PMC13152014, DOI: 10.1093/braincomms/fcag136.Peer-Reviewed Original ResearchAltmetricOptimized reference region and the effect on test-retest reliability and sensitivity to differences between Parkinson’s disease and control groups with [11C]UCB-J
Khattar N, Matuskey D, Gallezot J, Naganawa M, Holmes S, Sadabad F, Mayeli M, Esterlis I, van Dyck C, Mecca A, D’Souza D, Nabulsi N, Finnema S, Huang Y, Carson R, Toyonaga T. Optimized reference region and the effect on test-retest reliability and sensitivity to differences between Parkinson’s disease and control groups with [11C]UCB-J. Journal Of Cerebral Blood Flow And Metabolism : Official Journal Of The International Society Of Cerebral Blood Flow And Metabolism 2026, 0271678x261441071. PMID: 41960765, PMCID: PMC13068773, DOI: 10.1177/0271678x261441071.Peer-Reviewed Original ResearchAltmetricSynaptic density imaging in behavioral variant frontotemporal dementia: A comparison of 18F‐SynVesT‐1 and 18F‐FDG PET
Fesharaki‐Zadeh A, Cayir S, Ibrahim W, Yang Y, Gallezot J, Naganawa M, Wu Y, Toyonaga T, Sadabad F, O'Dell R, Pittman B, Nabulsi N, Strittmatter S, Carson R, Huang Y, van Dyck C, Mecca A, Matuskey D. Synaptic density imaging in behavioral variant frontotemporal dementia: A comparison of 18F‐SynVesT‐1 and 18F‐FDG PET. Alzheimer's & Dementia 2026, 22: e71283. PMID: 41954197, PMCID: PMC13063251, DOI: 10.1002/alz.71283.Peer-Reviewed Original ResearchThis study investigates synaptic density imaging in behavioral variant frontotemporal dementia, showing that SV2A PET detects more pronounced synaptic loss than glucose hypometabolism using FDG PET, aiding early diagnosis and monitoring.Variance reduction with synaptic density imaging in Parkinson’s disease using direct-4D PET image reconstruction
Gravel P, Gallezot J, Fontaine K, Matuskey D, Carson R. Variance reduction with synaptic density imaging in Parkinson’s disease using direct-4D PET image reconstruction. Physics In Medicine And Biology 2026, 71: 065007. PMID: 41825140, PMCID: PMC13014069, DOI: 10.1088/1361-6560/ae520a.Peer-Reviewed Original ResearchAltmetricDose Reduction in Dynamic PET Imaging Using Self-Supervised Two-Step Deep Image Prior
Li A, Syed M, Naganawa M, Matuskey D, Carson R, Tang J. Dose Reduction in Dynamic PET Imaging Using Self-Supervised Two-Step Deep Image Prior. IEEE Transactions On Radiation And Plasma Medical Sciences 2026, PP: 1-1. DOI: 10.1109/trpms.2026.3671590.Peer-Reviewed Original ResearchCitationsDose reduction for synaptic density PET imaging in Parkinson’s disease
Li A, Naganawa M, Honhar P, Fontaine K, Gravel P, Matuskey D, Carson R, Tang J. Dose reduction for synaptic density PET imaging in Parkinson’s disease. NeuroImage 2026, 331: 121853. PMID: 41833889, DOI: 10.1016/j.neuroimage.2026.121853.Peer-Reviewed Original ResearchAltmetricSocial determinants of brain structure and cognition
Mayeli M, Matuskey D, Initiative F. Social determinants of brain structure and cognition. Social Science & Medicine 2026, 394: 119045. PMID: 41662789, PMCID: PMC13034436, DOI: 10.1016/j.socscimed.2026.119045.Peer-Reviewed Original ResearchAltmetric
Clinical Trials
Current Trials
Brain Connections & HIV Status
IRB ID2000033582RoleSub InvestigatorPrimary Completion Date12/31/2027Recruiting ParticipantsGenderBothAge18 years - 80 yearsM1 Schizophrenia PET Study
IRB ID2000031171RoleSub InvestigatorPrimary Completion Date04/30/2023Recruiting ParticipantsGenderBothAge18 years - 55 yearsEligibility for Participation in Neuroimaging Studies
IRB ID2000027842RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting ParticipantsHPA axis function in the brains of PTSD, Trauma Exposed, or Otherwise Healthy research participants utilizing PET and MRI imaging
IRB ID2000028748RoleSub InvestigatorPrimary Completion Date08/31/2025Recruiting ParticipantsGenderBothAge18 years - 55 yearsStudying the Adult Brain
IRB ID2000025671RoleSub InvestigatorPrimary Completion Date07/31/2025Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Honors
honor NARSAD Young Investigator Award
08/07/2018National AwardBrain & Behavior Research FoundationDetailsUnited Stateshonor Michael Kuhar Travel Award
08/23/2011International AwardInternational Drug and Alcohol Research SocietyDetailsUnited Stateshonor NIDA-ISAM Travel Fellowship
01/01/2011International AwardNIDA-ISAMDetailsUnited Stateshonor NARSAD Young Investigator Award
08/01/2010National AwardBrain & Behavior Research FoundationDetailsUnited States
News
Copy Link
News
- July 16, 2026Source: Molecular Psychiatry
Widespread Synaptic Density Loss in Schizophrenia Follows Molecular and Network Architecture
- June 25, 2026
Yale Child Study Center Recognizes Spring 2026 Award Recipients and Retirees
- June 05, 2026
Depression: The Hidden Toll of Parkinson's Disease
- April 09, 2026
Diagnosing Dementia: Neuroimaging Technique Could Speed Detection
Get In Touch
Copy Link
Contacts
Locations
801 Howard Avenue
Academic Office
New Haven, CT 06519